• Equity PC Ratio   0.57
  • |
  • Index PC Ratio   1.14
  • |
  • Total PC Ratio   0.97
  • |
  • VIX PC Ratio   0.54
  • VIX 16.88
  • VXN 20.43
  • VXO 17.83
  • ISEE 85.00

TruCharts Trading Strategies and Stock Buy/Sell Reports
(Show Details)

Chart Settings
No saved settings found!

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:

Indicator Windows:

PGNX (Progenics Pharmaceuticals Inc)
Last Trade 3.67 Date 8/21/2019
Change % 3.68 % Price Change 0.13
Open 3.52 52 Week High 8.11
High 3.73 52 Week Low 3.5
Low 3.42 Type stock
Volume 1238861 Avg Volume 777066
Prev Close 3.54 Stock Exchange NASDAQ
Company Profile

Progenics Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases in the United States and internationally. The company offers RELISTOR-Subcutaneous injection for the treatment of opioid-induced constipation in advanced illness patients receiving palliative care. It is also conducting a Phase I clinical trial of a human monoclonal antibody-drug conjugate directed against prostate specific membrane antigen (PSMA), a protein found at high levels on the surface of prostate cancer cells, as well as in blood vessels supplying other solid tumors. In addition, the company is developing therapeutic vaccines designed to stimulate an immune response to PSMA; PRO 140, a viral-entry inhibitor for human immunodeficiency virus (HIV), which is in Phase II clinical testing; and novel multiplex PI3-Kinase inhibitors to combat aggressive forms of cancer. Additionally, it engages in researching a prophylactic vaccine for HIV infection; and candidates that are HCV-entry inhibitors. The company was founded in 1986 and is based in Tarrytown, New York.